Metabolic Biomarker Testing Market Report 2025

This metabolic biomarker testing market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The metabolic biomarker testing market size has grown strongly in recent years. It will grow from $2.82 billion in 2024 to $3.06 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increasing prevalence of metabolic disorders, rising awareness about early disease detection, growing demand for personalized medicine, increasing prevalence of obesity and diabetes, and growing adoption of preventive healthcare measures.

The metabolic biomarker testing market size is expected to see strong growth in the next few years. It will grow to $4.2 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increasing focus on precision medicine, growth in personalized nutrition and wellness programs, increased funding for metabolic research, growing patient awareness and education, and rising prevalence of metabolic syndrome and related conditions. Major trends in the forecast period include advancements in high-throughput screening technologies, integration of artificial intelligence, integration of machine learning for biomarker analysis, advances in mobile health (mHealth) technologies, and expansion of telemedicine solutions for remote biomarker testing.

The increasing incidence of diabetes is expected to drive the growth of the metabolic biomarker testing market. Diabetes is a chronic condition marked by elevated blood glucose levels due to the body's inability to produce or properly use insulin. The rise in diabetes cases is influenced by poor dietary habits, particularly high consumption of processed foods and sugary drinks, along with sedentary lifestyles with minimal physical activity. Additionally, aging populations and family history of diabetes contribute to increased risk, indicating a genetic predisposition. Metabolic biomarker testing aids in diagnosing, monitoring, and managing metabolic diseases such as diabetes by providing detailed insights into metabolic functions and abnormalities at a molecular level. For example, in May 2024, the British Diabetic Association, a U.K.-based non-profit organization, reported that 4.3 million individuals in the UK are currently diagnosed with diabetes, with an increase of 148,951 cases in 2022 compared to 2021. Furthermore, over 2.4 million people in the UK are at high risk of developing type 2 diabetes. Thus, the rising incidence of diabetes is set to propel the growth of the metabolic biomarker testing market.

Major companies in the metabolic biomarker testing market are focusing on technological advancements, such as biowearables for self-monitoring, to enable users to continuously track and manage their nutritional and health indicators. These biowearables provide real-time, non-invasive monitoring of key metabolic markers such as glucose, supporting personalized health management and optimizing diet and athletic performance. For example, in January 2022, Abbott Laboratories, a US-based medical device company, introduced the Lingo biowearable. Designed to be worn on the upper arm for up to two weeks, it allows users to monitor glucose, ketone, and lactate levels, offering continuous insights into metabolic health. Utilizing technology from Abbott’s FreeStyle Libre, the device aims to enhance general wellness and athletic performance rather than serving as a medical diagnostic tool. The initial launch was planned for Europe under the Lingo Keto brand, making it available directly to consumers without a prescription.

In June 2024, Lifesum AB, a Sweden-based provider of a healthy eating and wellness platform, acquired Lykon GmbH for an undisclosed amount. This acquisition is intended to integrate Lykon's biomarker testing into Lifesum's platform, enhancing the ability to offer personalized health insights, expanding wellness services, and bolstering Lifesum's position in the advanced wellness market. Lykon GmbH, based in Germany, specializes in personalized metabolic and nutritional testing.

Major companies operating in the metabolic biomarker testing market are Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies Inc., PerkinElmer Inc., bioMérieux S.A., LECO Corporation, Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, SCIEX, Promega Corporation, Cayman Chemical Company, Metabolon Inc., Biocrates Life Sciences AG, Human Metabolome Technologies Inc., KineMed Inc., Evosep Biosystems A/S, Creative Proteomics Inc., Lipotype GmbH, Metabolomic Diagnostics Ltd, Stemina Biomarker Discovery Inc., Chenomx Inc., GlycoPath Pty Ltd.

North America was the largest region in the metabolic biomarker testing market in 2024. The regions covered in the metabolic biomarker testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metabolic biomarker testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Metabolic biomarker testing involves analyzing specific molecules in biological samples, such as blood or urine, to evaluate metabolic processes and identify imbalances or dysfunctions. This testing is crucial for diagnosing metabolic disorders, monitoring health conditions, and developing personalized treatment strategies.

The primary types of metabolic biomarker testing include separation techniques, detection techniques, and other methods. Separation techniques utilize physical or chemical processes to isolate specific metabolites from biological samples based on properties such as size, charge, or affinity. This process aids in purifying and accurately identifying metabolic biomarkers. Indications for testing cover areas such as cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and more. Applications include drug assessment, nutrigenomics, toxicology testing, personalized medicine, and functional genomics. End users of metabolic biomarker testing include pharmaceutical and biotech companies, diagnostic tool companies, healthcare IT providers, and clinical laboratories.

The metabolic biomarker testing market research report is one of a series of new reports that provides metabolic biomarker testing market statistics, including metabolic biomarker testing industry global market size, regional shares, competitors with an metabolic biomarker testing market share, detailed metabolic biomarker testing market segments, market trends and opportunities, and any further data you may need to thrive in the metabolic biomarker testing industry. This metabolic biomarker testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metabolic biomarker testing market consists of revenues earned by entities by providing services such as laboratory testing, analysis of blood, urine, and other biological samples, and personalized health assessments. The market value includes the value of related goods sold by the service provider or included within the service offering. The metabolic biomarker testing market also includes sales of diagnostic kits, assay reagents, and testing equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.